The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Molecular targeted therapies in hepatocellular carcinoma†
Open accessAbstract
Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with several genomic alterations. There is evidence of aberrant activation of several signaling cascades such as epidermal growth factor receptor (EGFR), Ras/extracellular signal-regulated kinase, phosphoinositol 3-kinase/mammalian target of rapamycin (mTOR), hepatocyte growth factor/mesenchymal-epithelial transition factor, Wnt, Hedgehog, and apoptotic signaling. Recently a multikinase inhibitor, sorafenib, has shown survival benefits in patients with advanced HCC. This advancement represents a breakthrough in the treatment of this complex disease and proves that molecular therapies can be effective in HCC. It is becoming apparent, however, that to overcome the complexity of genomic aberrations in HCC, combination therapies will be critical. Phase II studies have tested drugs blocking EGFR, vascular endothelial growth factor/platelet-derived growth factor receptor, and mTOR signaling. No relevant data has been produced so far in combination therapies. Future research is expected to identify new compounds to block important undruggable pathways, such as Wnt signaling, and to identify new oncogenes as targets for therapies through novel high-throughput technologies. Recent guidelines have established a new frame for the design of clinical trials in HCC. Randomized phase II trials with a time-to-progression endpoint are proposed as pivotal for capturing benefits from novel drugs. Survival remains the main endpoint to measure effectiveness in phase III studies. Patients assigned to the control arm should receive standard-of-care therapy, that is, chemoembolization for patients with intermediate-stage disease and sorafenib for patients with advanced-stage disease. Biomarkers and molecular imaging should be part of the trials, in order to optimize the enrichment of study populations and identify drug responders. Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Intermediate HCC (BCLC stage B): Untreated patients at an intermediate stage – BCLC B class (multinodular asymptomatic tumors without an invasive pattern) present a median survival of 16 months [139,164], or 49% at 2 year [133].”
BackgroundAltekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Self-citationHoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Emerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Arzumanyan, A., Reis, H. M. G. P. V., & Feitelson, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3449 · Cited by 800
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Self-citationFocal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationde Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Self-citationPlasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Self-citationKuang, D.-M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., Yin, X.-Y., & Zheng, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.041 · Cited by 499
Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma
Keating, G. M., & Santoro, A. (2009) · Drugs · doi:10.2165/00003495-200969020-00006 · Cited by 482
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Self-citationChen, C.-L., Uthaya Kumar, D. B., Punj, V., Xu, J., Sher, L., Tahara, S. M., Hess, S., & Machida, K. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.004 · Cited by 388
RetractedMechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J. (2012) · Hepatology · doi:10.1002/hep.25907 · Cited by 356
Shimizu, S., Takehara, T., Hikita, H., Kodama, T., Miyagi, T., Hosui, A., Tatsumi, T., Ishida, H., Noda, T., Nagano, H., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.024 · Cited by 343
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression
Yoo, B. K., Emdad, L., Su, Z.-Z., Villanueva, A., Chiang, D. Y., Mukhopadhyay, N. D., Mills, A. S., Waxman, S., Fisher, R. A., Llovet, J. M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36460 · Cited by 328
Self-citationTargeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Self-citationFunctional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4017 · Cited by 306
Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma
van Zijl, F., Zulehner, G., Petz, M., Schneller, D., Kornauth, C., Hau, M., Machat, G., Grubinger, M., Huber, H., & Mikulits, W. (2009) · Future Oncology · doi:10.2217/fon.09.91 · Cited by 305
Major achievements in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60381-0 · Cited by 283
Self-citationDysregulation of apoptosis in hepatocellular carcinoma cells
Fabregat, I. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.513 · Cited by 280
Angiogenesis in chronic liver disease and its complications: Angiogenesis in CLD
Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02369.x · Cited by 276
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Ikeda, M., Morizane, C., Ueno, M., Okusaka, T., Ishii, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx180 · Cited by 272
Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target
Wang, H., Lafdil, F., Kong, X., & Gao, B. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.536 · Cited by 269
Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection
Li, Y.-W., Qiu, S.-J., Fan, J., Zhou, J., Gao, Q., Xiao, Y.-S., & Xu, Y.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.044 · Cited by 268
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 264
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad
Nejak-Bowen, K. N., & Monga, S. P. S. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.12.010 · Cited by 260
Gender Disparity of Hepatocellular Carcinoma: The Roles of Sex Hormones
Yeh, S.-H., & Chen, P.-J. (2010) · Oncology · doi:10.1159/000315247 · Cited by 256
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Self-citationFrau, M., Feo, F., & Pascale, R. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.031 · Cited by 179
Met as a therapeutic target in HCC: Facts and hopes
Giordano, S., & Columbano, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.009 · Cited by 158
Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics
Li, K., Nejadnik, H., & Daldrup-Link, H. E. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.008 · Cited by 139
PARK, G. B., CHOI, Y., KIM, Y. S., LEE, H.-K., KIM, D., & HUR, D. Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2252 · Cited by 96
Meng, Z., Li, T., Ma, X., Wang, X., Van Ness, C., Gan, Y., Zhou, H., Tang, J., Lou, G., Wang, Y., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0314 · Cited by 97
AbouAitah, K., Swiderska-Sroda, A., Farghali, A. A., Wojnarowicz, J., Stefanek, A., Gierlotka, S., Opalinska, A., Allayeh, A. K., Ciach, T., & Lojkowski, W. (2018) · Oncotarget · doi:10.18632/oncotarget.25470 · Cited by 83
Calvisi, D. F., Simile, M. M., Ladu, S., Frau, M., Evert, M., Tomasi, M. L., Demartis, M. I., Daino, L., Seddaiu, M. A., Brozzetti, S., et al. (2011) · Hepatology · doi:10.1002/hep.24174 · Cited by 65
Liu, T.-C., Vachharajani, N., Chapman, W. C., & Brunt, E. M. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000218 · Cited by 37
Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model
Hatting, M., Spannbauer, M., Peng, J., Al Masaoudi, M., Sellge, G., Nevzorova, Y. A., Gassler, N., Liedtke, C., Cubero, F. J., & Trautwein, C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.590 · Cited by 30
Zhou, S., Ye, W., Duan, X., Zhang, M., & Wang, J. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2537-1 · Cited by 18
Retracted
Metadata
- Authors
- Llovet, J. M., & Bruix, J.
- Venue
- Hepatology
- Published
- 2008-10
- Volume
- 48
- Issue
- 4
- Pages
- 1312-1327
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1970060716
- Cited by
- 1,004
- References
- 79
- FWCI
- 58.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.